×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:IOVA

Iovance Biotherapeutics Stock Forecast, Price & News

$11.47
+0.43 (+3.89%)
(As of 07/1/2022 08:44 PM ET)
Add
Compare
Today's Range
$10.94
$11.62
50-Day Range
$6.38
$16.88
52-Week Range
$6.18
$27.96
Volume
4.14 million shs
Average Volume
3.53 million shs
Market Capitalization
$1.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.10

Iovance Biotherapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
127.6% Upside
$26.10 Price Target
Short Interest
Healthy
11.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
0.29mentions of Iovance Biotherapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$74.84 K Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.49) to ($2.21) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.53 out of 5 stars

Medical Sector

82nd out of 1,412 stocks

Biological Products, Except Diagnostic Industry

12th out of 215 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Iovance Biotherapeutics logo

About Iovance Biotherapeutics (NASDAQ:IOVA) Stock

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

IOVA Stock News Headlines

7 Analysts Have This to Say About Iovance Biotherapeutics
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 4.7%
Iovance Biotherapeutics (NASDAQ:IOVA) Trading 3.4% Higher
Why Iovance Biotherapeutics Was Halved Today
Iovance: Onward To Approval
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IOVA
Fax
N/A
Employees
319
Year Founded
N/A

Company Calendar

Last Earnings
5/05/2022
Today
7/03/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$26.10
High Stock Price Forecast
$43.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+127.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88888888888889
Research Coverage
9 Analysts

Profitability

Net Income
$-342.25 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.96 per share

Miscellaneous

Free Float
145,223,000
Market Cap
$1.80 billion
Optionable
Optionable
Beta
0.46














Iovance Biotherapeutics Frequently Asked Questions

Should I buy or sell Iovance Biotherapeutics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Iovance Biotherapeutics stock.
View analyst ratings for Iovance Biotherapeutics
or view top-rated stocks.

What is Iovance Biotherapeutics' stock price forecast for 2022?

9 Wall Street analysts have issued 1 year target prices for Iovance Biotherapeutics' shares. Their IOVA stock forecasts range from $13.00 to $43.00. On average, they anticipate Iovance Biotherapeutics' share price to reach $26.10 in the next twelve months. This suggests a possible upside of 127.6% from the stock's current price.
View analysts' price targets for Iovance Biotherapeutics
or view top-rated stocks among Wall Street analysts.

How has Iovance Biotherapeutics' stock price performed in 2022?

Iovance Biotherapeutics' stock was trading at $19.09 at the start of the year. Since then, IOVA stock has decreased by 39.9% and is now trading at $11.47.
View the best growth stocks for 2022 here
.

When is Iovance Biotherapeutics' next earnings date?

Iovance Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Iovance Biotherapeutics
.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) released its quarterly earnings data on Thursday, May, 5th. The biotechnology company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.06. The biotechnology company earned $12 million during the quarter. The company's quarterly revenue was up .0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.51) earnings per share.
View Iovance Biotherapeutics' earnings history
.

Who are Iovance Biotherapeutics' key executives?

Iovance Biotherapeutics' management team includes the following people:
  • Dr. Frederick G. Vogt Esq., J.D., Ph.D., Interim CEO, Pres, Gen. Counsel & Corp. Sec. (Age 48, Pay $752.81k)
  • Mr. Jean-Marc Bellemin M.B.A., Chief Financial Officer & Principal Accounting Officer (Age 50, Pay $623.6k)
  • Dr. Igor P. Bilinsky, Chief Operating Officer (Age 49, Pay $577.35k)
  • Dr. Friedrich Graf Finckenstein M.D., Chief Medical Officer (Age 55, Pay $649.13k)
  • Ms. Sara Pellegrino, VP of Investor Relations & PR
  • Ms. Tracy Winton, Sr. VP of HR
  • Mr. Howard B. Johnson M.B.A., Chief Bus. Officer (Age 62)
  • James Ziegler, Sr. VP of Commercial
  • Mr. Madan Jagasia, Sr. VP of Medical Affairs
  • Dr. Raj K. Puri M.D., Ph.D., Exec. VP of Regulatory Strategy & Translational Medicine

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $11.47.

How much money does Iovance Biotherapeutics make?

Iovance Biotherapeutics (NASDAQ:IOVA) has a market capitalization of $1.80 billion. The biotechnology company earns $-342.25 million in net income (profit) each year or ($2.29) on an earnings per share basis.

How many employees does Iovance Biotherapeutics have?

Iovance Biotherapeutics employs 319 workers across the globe.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The official website for Iovance Biotherapeutics is www.iovance.com. The biotechnology company can be reached via phone at (650) 260-7120 or via email at achang@troutgroup.com.

This page (NASDAQ:IOVA) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.